Palifermin for management of treatment-induced oral mucositis in cancer patients.
Oral mucositis (OM) remains a major side effect of various cancer therapies, which exacts a significant price in terms of morbidity and cost of care. Efforts aimed at prevention and/or therapy of OM have been largely unsuccessful. Few agents have shown efficacy, and even those were applicable to limited types of patients. The advent of small-molecule targeted agents opened new possibilities for intervention in the mucopathogenic processes induced by cancer therapies. One of these agents, recombinant human keratinocyte growth factor (KGF), has been studied extensively and has shown promising results in reducing chemotherapy induced OM. This drug's effects on stem cell engraftment, graft-versus-host disease and other treatment-induced morbidities remain undefined. In this article we evaluate the pre-clinical and clinical evidence and discuss the clinical applications of KGF as an adjunct therapeutic agent in oncology.
Barasch
Andrei
A
Department of Diagnostic Sciences, University of Alabama at Birmingham, Birmingham, AL, USA. abarasch@uab.edu
Epstein
Joel
J
Tilashalski
Ken
K
Nat Rev Cancer. 2004 Apr;4(4):277-84
15057287
Bone Marrow Transplant. 2007 Nov;40(10):983-8
17846600
Cell Prolif. 2002 Aug;35 Suppl 1:86-92
12139711
J Clin Endocrinol Metab. 2003 Feb;88(2):773-80
12574212
N Engl J Med. 2004 Dec 16;351(25):2590-8
15602019
Curr Pharm Des. 2002;8(5):395-403
12069377
J Clin Oncol. 2001 Apr 15;19(8):2201-5
11304772
Cancer Chemother Pharmacol. 2002 Sep;50(3):202-12
12203102
J Clin Oncol. 2008 May 20;26(15):2489-96
18487568
Anticancer Res. 2002 Sep-Oct;22(5):2539-45
12529961
Cancer Res. 1998 Mar 1;58(5):933-9
9500453
Bone Marrow Transplant. 2008 Aug;42(4):275-9
18500368
Biol Blood Marrow Transplant. 2008 Sep;14(9):1017-1021
18721764
Cell Prolif. 2002 Aug;35 Suppl 1:78-85
12139710
J Clin Oncol. 2003 Apr 15;21(8):1452-8
12697866
Support Care Cancer. 2008 May;16(5):477-83
17710442
Cell Prolif. 2002 Aug;35 Suppl 1:32-47
12139706
Int J Radiat Biol. 2001 Mar;77(3):341-7
11258848
Mol Cancer Res. 2008 Aug;6(8):1337-46
18708365
Cell Biol Int. 1995 May;19(5):399-411
7640656
Cancer Chemother Pharmacol. 2002 Jul;50(1):53-8
12111112
J Clin Oncol. 2006 Nov 20;24(33):5194-200
17075109
Support Cancer Ther. 2004 Jul 1;1(4):219-29
18628146
Oral Oncol. 2003 Feb;39(2):91-100
12509961
Blood. 2007 Jul 1;110(1):441-9
17374737
Int J Radiat Biol. 1999 May;75(5):609-20
10374943
PLoS One. 2008 Jun 25;3(6):e2528
18575591
Stem Cells. 2008 Oct;26(10):2595-601
18669914
Clin Cancer Res. 2004 Dec 15;10(24):8318-24
15623608
Biol Blood Marrow Transplant. 2007 Jul;13(7):806-13
17580258
Blood. 2000 Dec 15;96(13):4350-6
11110712
Ann Oncol. 2008 Sep;19(9):1644-9
18453519
Eur J Oral Sci. 2003 Feb;111(1):42-50
12558807
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):177-87
9422575
Support Care Cancer. 2007 Jan;15(1):105-9
16896881
Clin Cancer Res. 2003 Aug 15;9(9):3454-61
12960137
Pharmacol Res. 2002 Aug;46(2):179-83
12220958
Gene Ther. 2002 Aug;9(16):1065-74
12140734
Support Cancer Ther. 2005 Jan 1;2(2):122-7
18628199